candesartan and exp-3179

candesartan has been researched along with exp-3179 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Schieffer, B; Schmidt, B	1
Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T	1
Foster, H; Foster, R; Philippou, H; Wilson, C	1

Reviews

1 review(s) available for candesartan and exp-3179

Article	Year
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. Journal of medicinal chemistry, 2003, Jun-05, Volume: 46, Issue:12 Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Growth Hormone; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Thromboxane A2	2003

Article

Year

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.

Journal of medicinal chemistry, 2003, Jun-05, Volume: 46, Issue:12

Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Growth Hormone; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Thromboxane A2

2003

Other Studies

2 other study(ies) available for candesartan and exp-3179

Article	Year
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5 Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents	2011
Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis. Journal of medicinal chemistry, 2020, 11-12, Volume: 63, Issue:21 Topics: Binding Sites; Biological Products; Humans; Ligands; Losartan; Molecular Dynamics Simulation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Signal Transduction; Small Molecule Libraries; Thrombosis	2020

Article

Year

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.

Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5

Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents

2011

Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.

Journal of medicinal chemistry, 2020, 11-12, Volume: 63, Issue:21

Topics: Binding Sites; Biological Products; Humans; Ligands; Losartan; Molecular Dynamics Simulation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Signal Transduction; Small Molecule Libraries; Thrombosis

2020